http://www.cnr.it/ontology/cnr/individuo/prodotto/ID109060

Pioglitazone Treatment Increases Whole Body Fat But Not Total Body Water in Patients with on-Alcoholic Steatohepatitis ( ASH) (Abstract/Poster in atti di convegno)

Type

Label

Pioglitazone Treatment Increases Whole Body Fat But Not Total Body Water in Patients with on-Alcoholic Steatohepatitis ( ASH) (Abstract/Poster in atti di convegno) (literal)

Anno

Alternative label

Balas B.; Belfort R.; Harrison S. A.; Darland C.; Finch J.; Gastaldelli A.; Cusi K. (2007)
Pioglitazone Treatment Increases Whole Body Fat But Not Total Body Water in Patients with on-Alcoholic Steatohepatitis ( ASH)
in Annual Meeting of American Diabetes Association, Chicago, 22-26 giugno 2007
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Balas B.; Belfort R.; Harrison S. A.; Darland C.; Finch J.; Gastaldelli A.; Cusi K. (literal)

Pagina inizio

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

In: Annual Meeting of American Diabetes Association (Chicago, 22-26 giugno 2007). Proceedings, pp. A164 - A164. American Diabetes Association, 2007. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

Results: Non-Alcoholic Steatohepatitis (NASH) is a chronic liver disease frequently associated with insulin resistance and type 2 diabetes mellitus (T2DM), and characterized by steatosis and necroinflammation with or without perisinusoidal fibrosis. We have recently reported that 6 months treatment with pioglitazone (PIO) reverses the metabolic and histological abnormalities of patients with IGT or T2DM and NASH, but also leads to weight gain. We performed a careful evaluation to understand the nature of weight gain associated with PIO treatment in NASH, as it may be important to establish the safety of its use in this population. To this end we analyzed a subgroup of 35 patients who completed the tests for determination of whole body fat (WBF) and total body water (TBW): 21 patients received PIO (9 IGT/12 T2DM) and 14 placebo (6 IGT/8 T2DM), in a double-blind, randomized fashion for a period of 6 months. WBF and TBW were measured before and after treatment using dual energy X-ray absorptiometry (DXA, Hologic Inc, Waltham, MA), a water dilution technique using 3H2O and bioimpedance. Results: PIO increased body weight (from 93.6±19.2 to 96.1±20.8 kg, p0.003) and WBF as measured by DXA (from 31.8±8.3 to 33.9±9.6 kg, p0.003) while no changes were seen with placebo. Total body water measured with 3H2O was not altered significantly either after PIO (from 45.0±10.5 to 45.3±9.6) or placebo (from 44.5±9.9 to 44.6±12.5 l), p (literal)

Note